Login / Signup

Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel.

Keisuke AndoShinichi SakamotoNobushige TakeshitaAyumi FujimotoMaihulan MaimaitiShinpei SaitoPae SanjyonYusuke ImamuraNobuo SatoAkira KomiyaKoichiro AkakuraTomohiko Ichikawa
Published in: The Prostate (2019)
The present study identified higher serum testosterone (≥13 ng/dL) as a significant prognostic factor in castration-resistant prostate cancer patients treated with docetaxel therapy.
Keyphrases
  • poor prognosis
  • prognostic factors
  • long non coding rna
  • replacement therapy
  • radiation therapy
  • stem cells
  • bone marrow
  • mesenchymal stem cells